CYAD Stock Price, News & Analysis

Celyad Oncology (CYAD) provided a business update for Q3 2020, emphasizing advancements in its clinical pipeline. Key highlights include a partnership with MSD for a Phase 1b trial of CYAD-101 combined with KEYTRUDA in metastatic colorectal cancer (mCRC) patients. The company is set to initiate the IMMUNICY-1 trial for CYAD-211 by year-end 2020, targeting relapsed/refractory multiple myeloma. As of September 30, 2020, Celyad reported a cash position of €20 million ($23.4 million) and a net cash burn of €6.7 million ($7.8 million), confirming sufficient funds through Q3 2021.

Celyad Oncology (CYAD) announced that three abstracts were accepted for presentation at the 62nd American Society of Hematology Annual Meeting, occurring virtually from December 5-8, 2020. The abstracts will focus on the company’s CAR T candidates: the allogeneic CYAD-211 targeting BCMA, and the autologous CYAD-01 and CYAD-02 based on the NKG2D receptor. The findings will be published in the November issue of the journal Blood. CYAD-211 has received FDA clearance for its IND application, representing progress in CAR T therapy development for multiple myeloma and related cancers.

Celyad Oncology SA (Euronext & Nasdaq: CYAD) has announced its participation in three upcoming healthcare conferences in November 2020. The events are: Bryan, Garnier & Co. Virtual European Healthcare Conference on November 16, Jefferies Virtual London Healthcare Conference on November 17 at 2:55 p.m. ET, and SVB Leerink Oncology 1x1 Day on November 19. The company focuses on developing CAR T therapies for cancer, supported by the Walloon Region funding. Investors can find more details on Celyad's website.

Celyad Oncology (NASDAQ:CYAD) has announced a collaboration with MSD to conduct the Phase 1b KEYNOTE-B79 clinical trial. This trial will investigate the investigational allogeneic CAR T candidate, CYAD-101, in combination with MSD's KEYTRUDA® for treating refractory metastatic colorectal cancer patients. The collaboration aims to leverage the complementary mechanisms of both therapies, potentially addressing unmet needs in microsatellite stable disease. Encouraging results from the alloSHRINK trial provide a positive backdrop for this initiative.

Celyad Oncology, a clinical-stage biotechnology company, announced that CEO Filippo Petti will participate in a fireside chat at the Jefferies Cell Therapy Summit on October 5, 2020, at 11:00 a.m. EDT. The event will be available for investors to listen to via a live webcast on the company's website, with an archived replay accessible for 30 days. Celyad focuses on developing CAR T cell therapies for cancer, including allogeneic and autologous candidates for treating hematological malignancies and solid tumors. The company, founded in 2007, is based in Belgium and New York.

Celyad Oncology (CYAD), a clinical-stage biotechnology company, will host a Research & Development webinar on September 29 at 11:00 a.m. EDT. The webinar will provide insights on its CAR T candidates, CYAD-101 for metastatic colorectal cancer and CYAD-211 for relapsed/refractory multiple myeloma. Dr. Richard Kim will discuss immuno-oncology treatments. Celyad's management will share updates on its pipeline and future directions. Interested participants can register for the live webcast through the company's website, where a replay will also be available post-event.

Celyad Oncology has announced an Open Market Sale Agreement with Jefferies LLC to sell up to $25 million of new American Depositary Shares (ADSs) through an at-the-market offering. The ADSs are priced at $9.91 each, representing a potential issuance of up to 2,777,777 shares. Proceeds from this offering will primarily support the company's CAR T cell therapy research and development initiatives. The offering is registered under a shelf registration statement effective as of September 4, 2020, with additional details available from Jefferies.

Celyad Oncology SA (CYAD) announced its participation in several conferences in September 2020, including the Wells Fargo 2020 Virtual Healthcare Conference and the H.C. Wainwright 22nd Annual Global Investment Conference. The company, based in Mont-Saint-Guibert, Belgium, focuses on developing CAR T cell therapies for cancer. Celyad is advancing both allogeneic and autologous therapy candidates for hematological malignancies and solid tumors. The press release includes a forward-looking statement about the expected initiation of a Phase 1 trial by year-end 2020.

Celyad Oncology announced that the FDA has granted permission for the Phase 1 clinical trial of CYAD-211, its first shRNA-based allogeneic CAR T candidate targeting BCMA for relapsed/refractory multiple myeloma. The trial is set to begin by the end of 2020. CYAD-211 is part of the CYAD-200 series and utilizes a unique shRNA technology platform. This marks a significant advancement for Celyad, demonstrating its ability to effectively develop multiple off-the-shelf CAR T therapies.